Rifampicin-resistant tuberculosis
diseaseOn this page
Also known as rifampicin-resistant TBRR-TB
Summary
Rifampicin-resistant tuberculosis (MONDO:0100479) is a disease and 11 clinical trials. Top therapeutic interventions include bedaquiline, clofazimine, and ethambutol. A subtype of drug-resistant tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 11
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | rifampicin-resistant tuberculosis |
| Mondo ID | MONDO:0100479 |
| UMLS | C1532782 |
| MedGen | 735456 |
| GARD | 0026238 |
| Is cancer (heuristic) | no |
Also known as: rifampicin-resistant TB · RR-TB
Disease family
This is a subtype of drug-resistant tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › drug-resistant tuberculosis › rifampicin-resistant tuberculosis
Related subtypes (3): multidrug-resistant tuberculosis, extensively drug-resistant tuberculosis, totally drug-resistant tuberculosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 11.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| Not specified | 4 |
| PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05081401 | PHASE3 | RECRUITING | Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB) |
| NCT06081361 | PHASE3 | ACTIVE_NOT_RECRUITING | Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort |
| NCT07268664 | PHASE3 | NOT_YET_RECRUITING | Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort |
| NCT04062201 | PHASE3 | COMPLETED | Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care |
| NCT07170800 | PHASE2 | RECRUITING | A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets |
| NCT07393438 | PHASE2 | NOT_YET_RECRUITING | Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) |
| NCT05586230 | PHASE1 | COMPLETED | Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis |
| NCT06565806 | Not specified | NOT_YET_RECRUITING | French National Cohort of Patients With Rifampicin-Resistant Tuberculosis |
| NCT02984579 | Not specified | COMPLETED | Line Probe Assay Evaluation Study |
| NCT03044158 | Not specified | COMPLETED | GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| NCT05017324 | Not specified | UNKNOWN | Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEDAQUILINE | 4 | 2 |
| CLOFAZIMINE | 4 | 2 |
| ETHAMBUTOL | 4 | 2 |
| LINEZOLID | 4 | 2 |
| PYRAZINAMIDE | 4 | 2 |
| ACETOHYDROXAMIC ACID | 4 | 1 |
| AMINOSALICYLIC ACID | 4 | 1 |
| CYCLOSERINE | 4 | 1 |
| DELAMANID | 4 | 1 |
| ISONIAZID | 4 | 1 |
| MOXIFLOXACIN | 4 | 1 |
| PRETOMANID | 4 | 1 |
| CONTEZOLID | 3 | 1 |
| PROTIONAMIDE | 3 | 1 |
| CHEMBL5285059 | 0 | 1 |
| CHEMBL4761573 | 0 | 1 |
| CHEMBL4746300 | 0 | 1 |